TEVA, VRX And AGN, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 17,082 as of Monday, Aug. 25, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,780 issues advancing vs. 1,159 declining with 188 unchanged.

The Drugs industry currently sits up 1.2% versus the S&P 500, which is up 0.4%. Top gainers within the industry include InterMune ( ITMN), up 35.4%, Incyte ( INCY), up 5.7%, Illumina ( ILMN), up 2.4%, Gilead ( GILD), up 2.3% and Sanofi ( SNY), up 2.2%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.68 (-1.3%) to $52.77 on light volume. Thus far, 1.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $52.67-$53.37 after having opened the day at $53.22 as compared to the previous trading day's close of $53.45.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $45.8 billion and is part of the health care sector. Shares are up 33.4% year-to-date as of the close of trading on Friday. Currently there are 10 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon